Trials / Completed
CompletedNCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 282 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Dulaglutide | Administered SC |
Timeline
- Start date
- 2022-11-30
- Primary completion
- 2024-07-15
- Completion
- 2024-08-12
- First posted
- 2022-10-03
- Last updated
- 2025-08-03
- Results posted
- 2025-08-03
Locations
38 sites across 5 countries: United States, Belgium, Germany, Mexico, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05564039. Inclusion in this directory is not an endorsement.